Vaccinex presents pepinemab data at conferences; AD study completion expected Jun 2024, cancer ORR doubled

VACCINEX, INC.

Pepinemab presentations at Keystone Symposia (Oct 1-5) and CTAD (Oct 24-27) featuring AD and cancer data.
SIGNAL-AD phase 1/2a fully enrolled; last patient completes treatment by June 2024; key endpoints FDG-PET, CDR-SB, ADAS-Cog13.
KEYNOTE-B84: In PD-L1 low HNSCC (CPS<20), ORR 21.1% and median PFS 5.79 months, ~2x historical checkpoint monotherapy.
Combination with KEYTRUDA induces organized lymphoid structures correlated with disease control and PFS (p=0.0056).
Vaccinex and Merck in preliminary stages of potential extension study adding chemotherapy to pepinemab+KEYTRUDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.